New Study Reveals How BPA in Plastics Could Fuel Breast Cancer Growth

A team of scientists at the University of Texas at Arlington has made an important discovery about a chemical found in everyday products. Their research could help us understand how this chemical, BPA, May Affect Breast Cancer Growth.

What Is HOTAIR and Why Is It Important?

The researchers, led by Dr. Subhrangsu Mandal, looked at how BPA interacts with a molecule in our bodies called HOTAIR. HOTAIR is a part of our DNA that doesn’t make proteins but can still cause problems. It has been connected to several types of cancer, including breast cancer, because it can stop certain genes that help fight cancer from doing their job.

In their study, Dr. Mandal and his team found that when they exposed breast cancer cells to BPA, the chemical caused more HOTAIR to be produced. This was true even in normal breast tissue, not just in cancer cells. The problem with this is that higher amounts of HOTAIR could help cancer grow, making it harder for our bodies to fight the disease.

How Does BPA Affect Our Hormones?

BPA is used in many plastic products, like water bottles and food containers, and can also be found in the lining of canned foods. It’s part of a group of chemicals called endocrine disruptors, which can mess with our body’s hormones. Hormones help control important processes, like growth and development, so when they are affected, it can lead to health problems like early puberty, obesity, and even cancer.

One of the things the researchers discovered is that BPA might mess with the way estrogen, a natural hormone, works in the body. Estrogen usually helps control how much HOTAIR is made, but BPA can stop estrogen from doing its job properly. This could be one reason why BPA might help cancer grow.

Why This Research Matters

Dr. Mandal says the research is important because it helps us understand how chemicals like BPA could affect our health, especially as we learn more about how our hormones work. The team is continuing to study this to see if BPA and other chemicals can be stopped from causing problems like cancer.

“It’s important to know how chemicals in the environment could be affecting us in ways we can’t always see,” said Dr. Mandal.

The study’s results were published in a scientific journal called Journal of Steroid Biochemistry and Molecular Biology, and researchers hope their findings will help people understand the risks of using certain chemicals in everyday products.

While the study does not prove that BPA directly causes cancer, it does suggest that BPA may play a role in making cancer grow. This is a reminder to be careful with plastics and other products that might contain BPA and to keep learning about how the things we use can affect our health.

Researchers will continue their work to learn more about BPA and how it affects our bodies. Until then, experts suggest we pay attention to what’s in the products we use every day.

Stay informed and engaged with the latest advancements. Empower yourself with knowledge and make more informed decisions about your breast cancer treatment and care. Visit the Breast Advocate App website today and join us in the fight against breast cancer.

New Research Could Help Understand Breast Cancer Spread to Bone

Researchers from Tampere University in Finland and Izmir Institute of Technology in Turkey have created a new lab model. This model helps study why breast cancer often spreads to bones.

Breast Cancer Statistics

Breast cancer is a major health issue worldwide. Every year, there are 2.3 million new cases and about 700,000 deaths. Most patients with early-stage breast cancer can be cured if treated quickly. However, many patients have cancer that has already spread, making it harder to treat.

When cancer spreads, it becomes metastatic and is usually not curable. This type of cancer causes more than 90% of cancer deaths.

Currently, there are no good lab models to study how breast cancer spreads to bones, lungs, liver, or brain.

Innovative Research Approach

The new research team has developed a model using lab-on-a-chip technology. This model mimics how breast cancer spreads to bones. Burcu Firatligil-Yildirir, a researcher at Tampere University, explained, “Breast cancer often spreads to bones, causing severe pain and other issues. Our model helps understand how this happens.”

Nonappa, the leader of the research team, noted that creating these lab models is complex. It requires knowledge from different fields, including cancer biology and materials science. He added, “Our work shows that we can build realistic lab models. These could help predict cancer spread and improve diagnosis and treatment options.”

Future Possibilities

This research opens new possibilities for better understanding and fighting breast cancer.

New Study Confirms 3D Mammograms Find More Cancers Early

A new 10-year study shows that 3D mammography, also known as Digital Breast Tomosynthesis (DBT), improves cancer detection. It also reduces the number of advanced cancer cases compared to traditional 2D mammograms. The findings were published in Radiology, a journal by the Radiological Society of North America (RSNA).

Mammograms are the gold standard for detecting breast cancer early. However, 2D mammograms can miss 20% of breast cancers. These traditional methods also lead to more false-positive results, which means unnecessary follow-up tests.

What is 3D Mammography (DBT)?

DBT creates a 3D image of the breast by taking pictures from several angles. This makes it easier for doctors to detect cancer. Studies show that DBT detects more cancers than traditional 2D mammography.

This study compared breast cancer detection using DBT and traditional digital mammograms over 10 years. Researchers at Yale University and Yale-New Haven Health studied over 272,000 mammograms. Most of these mammograms were done using DBT. The study found that DBT detected 1,265 cancers, while 2D mammography found 142 cancers.

Earlier Detection of Aggressive Cancers

DBT detected 5.3% of cancers, compared to 4.0% with traditional mammograms. Importantly, DBT reduced the number of advanced cancers from 43.6% to 32.7%. This means DBT finds cancers at an earlier, more treatable stage.

DBT also reduced the number of women called back for further tests. Only 7.2% of women screened with DBT needed more testing. In comparison, 10.6% of women screened with 2D mammograms were recalled.

A Positive Step for Breast Cancer Screening

DBT helps find cancers earlier while reducing unnecessary follow-up tests. Dr. Liane Philpotts, one of the study’s lead authors, believes this is a positive step forward. She said, “DBT’s lower recall rate and higher cancer detection rate is a win for everyone.”

Future of Breast Cancer Screening

This study encourages healthcare centers to switch to DBT for breast cancer screening. The researchers hope more studies will confirm the benefits of 3D mammography. For now, the results show that DBT is better at detecting cancer early, which can improve patient outcomes.

DBT’s success gives women a greater chance of early detection and effective treatment.

Annual Mammograms Linked to Better Breast Cancer Outcomes, Study Finds

Women diagnosed with breast cancer who had annual mammograms were less likely to face late-stage cancer and had better overall survival rates. This is according to new research from the University of Pittsburgh and UPMC, published in the Journal of Clinical Oncology.

Study Highlights

The study found that only about 65% of women over age 40 are screened for breast cancer, and only half of these women receive annual screenings. Conflicting guidelines have made it unclear how often women should get screened. The American College of Radiology suggests annual screenings after age 40, while the U.S. Preventive Services Task Force recommends biennial screenings starting at 40.

To address this, researchers used a large database to analyze real-world outcomes for 8,145 breast cancer patients who had at least one mammogram before their diagnosis. They compared the results based on screening intervals: annual (less than 15 months between mammograms), biennial (15 to 27 months), and intermittent (more than 27 months).

Key Findings

The study revealed that 9% of women who had annual screenings had late-stage cancer (stage IIB or worse). In comparison, 14% of those screened biennially and 19% of those with intermittent screenings had late-stage cancer. Additionally, those with annual screenings had significantly better survival rates.

Dr. Margarita Zuley, the study’s lead author, emphasized the benefits of annual mammograms. “Annual screenings are crucial for early detection, which improves survival rates and reduces the intensity of treatments needed,” she said.

Balancing Risks and Benefits

While annual mammograms are beneficial, they can also lead to false positives, causing unnecessary biopsies and anxiety. Dr. Zuley acknowledged these concerns but argued that the benefits of early detection outweigh the risks. The team is also working on developing screening tools with fewer false positives.

The study was supported in part by the National Cancer Institute. For more details, visit University of Pittsburgh.Annual Mammograms Linked to Better Breast Cancer Outcomes, Study Finds

Breakthrough Discovery Maps DNA’s Hidden Structures

Sydney, Australia – Researchers at the Garvan Institute of Medical Research have made a groundbreaking discovery. They have uncovered hidden DNA structures that could change disease treatment and diagnosis. Published today in The EMBO Journal, the study maps over 50,000 i-motifs, unusual knot-like structures in the human genome.

Unveiling the Mysteries of DNA

DNA is well-known for its double helix shape, but the human genome also contains over 50,000 i-motifs, unique structures discovered by the Garvan Institute. Unlike the double helix, i-motifs form a four-stranded, twisted shape when cytosine bases pair together.

This new study builds on a 2018 breakthrough where Garvan scientists first visualized i-motifs in living cells. Using a new antibody tool, researchers have now mapped these structures across the genome, revealing their widespread presence in key regions that regulate gene activity.

Dynamic Roles and Potential in Cancer Research

“In this study, we mapped over 50,000 i-motif sites in the human genome,” says Professor Daniel Christ. He is the senior author and Head of the Antibody Therapeutics Lab at Garvan.”The sheer number of these structures challenges previous notions and highlights their potential significance in genomic function and disease.”

I-motifs are concentrated in areas of the genome crucial for gene activity regulation. Notably, these structures are found in the promoter regions of oncogenes, such as the MYC oncogene, known for its role in cancer. This discovery suggests that i-motifs may play a dynamic role in gene regulation. Presenting an exciting opportunity for targeting disease-linked genes through novel therapeutic approaches.

Cristian David Peña Martinez, a research officer, notes, “Our findings indicate that i-motifs are associated with genes active during critical phases of the cell cycle, suggesting their involvement in regulating gene expression. Their presence in oncogenes, like MYC, opens up new avenues for targeted cancer therapies.”

New Horizons for Diagnostics and Therapeutics

Associate Professor Sarah Kummerfeld, emphasizes the potential impact of this discovery: “The widespread presence of i-motifs near important genetic sequences involved in hard-to-treat cancers could lead to the development of targeted drugs and diagnostic tools. Expanding current treatment options.”

The study’s success was made possible by Garvan’s expertise in antibody development and genomics. Thus illustrating how fundamental research and technological advancements can lead to transformative discoveries in medicine.

Funding for this research was provided by the National Health and Medical Research Council.

Professor Daniel Christ and Associate Professor Sarah Kummerfeld are also Conjoint Professors at St Vincent’s Clinical School. Further enhancing the collaborative nature of this groundbreaking research.

For further details, visit Garvan Institute.

New Study Reveals Alarming Rise in Breast Cancer Rates Among Younger Generations

A new American Cancer Society study reveals a troubling rise in cancer rates, including breast cancer, among younger generations. Published in The Lancet Public Health, the study analyzes cancer data from 2000 to 2019, showing a significant increase in several cancer types, especially among those born after 1990.

Significant Increase in Breast Cancer Incidence

Dr. Hyuna Sung, the lead author of the study and senior principal scientist of surveillance and health equity science at ACS, notes that this research expands on previous findings related to early-onset colorectal cancer and obesity-associated cancers. “Our findings reveal a consistent increase in cancer rates among younger cohorts, particularly for breast cancer, which shows a significant rise in estrogen-receptor positive cases,” Dr. Sung explains. “The exact reasons for these trends remain unclear, but the data underscores the need to investigate the social, economic, and environmental factors impacting these younger birth cohorts.”

The study examined data from 23.7 million cancer cases and 7.3 million cancer deaths. It found that incidence rates for eight cancers, including breast cancer, were higher in those born in 1990 compared to those born in 1955. Notably, estrogen-receptor positive breast cancer cases have risen significantly among younger generations.

Mortality Trends Aligned with Increased Incidence

The study shows that breast cancer rates are about 12% higher in people born in 1990 compared to older generations. This increase is similar to trends in other cancers like uterine and colorectal cancer. Mortality rates for several cancers, including breast cancer, have also risen, highlighting the need for targeted prevention and intervention.

Dr. Ahmedin Jemal, senior vice president at ACS and study co-author, highlights the future impact of current trends. “If these patterns persist, the cancer burden could significantly rise in the coming decades. It’s crucial to address the risk factors to prevent this escalation.”

Call to Action for Healthcare Access and Policy

The study highlights the importance of accessible healthcare and early detection. Lisa Lacasse, president of ACS CAN, emphasizes the need for comprehensive health insurance. “Affordable healthcare for all ages is crucial for better cancer outcomes. ACS CAN will advocate for Medicaid expansion and permanent ACA tax subsidies to increase access to care.”

As the medical community and policymakers respond to these findings, the focus is on understanding and reducing cancer risk factors in younger generations. This study calls for more research, better prevention strategies, and stronger healthcare policies to address the rising cancer rates.

New Study Shows Simple Reminder Reduces Unnecessary Breast Cancer Surgery

Simple Reminder System Significantly Lowers Unneeded Breast Cancer Surgeries

A new study published today in JAMA Surgery highlights how a “nudge” is reducing unnecessary breast cancer surgery. The electronic health record “nudge” significantly cut the number of sentinel lymph node biopsies (SLNB) performed on older breast cancer patients, helping avoid overtreatment and improve patient care.

Benefits of the Electronic Health Record Nudge

SLNB is a procedure that helps determine if breast cancer has spread to the lymph nodes under the arm. However, it is not always necessary, particularly for older women with early-stage breast cancer. Dr. Priscilla McAuliffe, a breast surgical oncologist at UPMC Hillman Cancer Center, notes that the nudge serves as a helpful reminder for doctors to assess whether SLNB is needed based on individual patient factors.

Study Results and Impact

The research team implemented the nudge system in eight surgical clinics, finding a significant drop in SLNB procedures from 46.9% to 23.8% of eligible patients. The rate further decreased to 15.6% during a follow-up period. Surgeons reported that the nudge was easy to use and integrated well into their workflow.

Reducing Risks and Improving Patient Care

Using artificial intelligence, the study also analyzed patient records for signs of lymphedema, a potential side effect of SLNB. The rate of patients needing evaluation for lymphedema decreased from 6.2% to 3.6% after the nudge was introduced. Dr. Neil Carleton, the study’s lead author, emphasizes the importance of this reduction as lymphedema can significantly affect a patient’s quality of life.

Future Plans

The research team plans to extend the nudge to additional UPMC facilities and hopes to improve care for more patients, including those in community settings. This study is part of a larger effort to tailor breast cancer treatment to individual needs and reduce unnecessary procedures.

The findings from this study suggest that implementing a “nudge” is reducing unnecessary breast cancer surgery. This simple reminder system can effectively reduce overtreatment and improve patient outcomes in breast cancer care. The use of such tools represents a step towards more personalized and efficient healthcare.

New Insights into Preventing Breast Cancer Recurrence

image of Finnish researchers in a lab, Researchers testing experimental drug molecules targeting DUSP6 protein, Breast cancer patient undergoing treatment with HER2 inhibitors.

Treatment outcomes for breast cancer have improved over the years thanks to advancements in therapies. However, recurrence of breast cancer remains a significant challenge, even after long periods of apparent remission. Researchers in Finland made a groundbreaking discovery on DUSP6 protein in breast cancer recurrence. They found why dormant breast cancer cells awaken and resume growth, potentially leading to recurrence.

Understanding the Mechanism

In a recent study, Finnish cancer researchers focused on HER2-positive breast cancer cells, known for their aggressive behavior and resistance to treatment. These cells can lie dormant during therapy, only to reawaken later. The team, led by Professor Jukka Westermarck, identified a key player: the DUSP6 protein.

The Role of DUSP6

Researchers found DUSP6 increases when breast cancer cells resist HER2 inhibitors, restarting cell growth and treatment failure.

Promising Treatment Strategy

The study also revealed that blocking the DUSP6 protein significantly inhibited the growth of these resistant breast cancer cells. By administering experimental drug molecules that target DUSP6, researchers observed a remarkable improvement in the effectiveness of HER2 inhibitors. This combination therapy not only prevented cancer cell growth but also reduced the formation of metastases, particularly in the brain.

Future Implications

While the drugs used in the study are not yet ready for clinical use, the findings provide a promising direction for future cancer therapies. Inhibiting DUSP6 could potentially enhance the effectiveness of existing HER2 inhibitors and prevent recurrence in HER2-positive breast cancer cases that have become resistant to current treatments.

This research underscores the importance of understanding the mechanisms behind cancer recurrence. By targeting specific proteins like DUSP6, researchers hope to develop more effective therapies that can improve long-term outcomes for breast cancer patients. As this study moves forward, it offers hope for developing new strategies to combat breast cancer recurrence and improve overall survival rates.

New Hope for Breast Cancer Treatment: Targeting Cell Recycling to Stop Brain Tumors

University of Arizona Researchers Find New Way to Treat Breast Cancer That Spreads to the Brain

Understanding Autophagy: The Cancer Cell’s Recycling System

Tucson, AZ — Scientists at the University of Arizona Cancer Center have made an important discovery that could lead to better treatments for breast cancer, especially when it spreads to the brain. This type of cancer is very hard to treat, but the researchers have found a new way to attack it using hydroxychloroquine and lapatinib for breast cancer brain metastases.

When breast cancer cells move to the brain, they start acting differently. The researchers found that these cells use a process called autophagy much more than the original breast cancer cells. Autophagy is like a recycling system for cells. It helps cancer cells survive when they are under stress, such as when they are being attacked by cancer drugs.

“The outlook for people with breast cancer that has spread to the brain is not good, and it’s really hard to treat,” said Dr. Jennifer Carew, one of the main researchers. “But we found that if we stop the cancer cells from using this recycling system, we can stop them from growing in the brain.”

Blocking a Key Gene: A Breakthrough in Stopping Cancer Spread

In their study, the researchers discovered that by blocking a gene called ATG7, which is important for autophagy, they could stop breast cancer cells from spreading to the brain in mice. Next, they looked for a drug that could do this in people.

They found that an existing drug, hydroxychloroquine, could help. This drug is already approved by the Food and Drug Administration (FDA). Additionally, it can cross the blood-brain barrier, which means it can get into the brain where many other drugs cannot.

“Most drugs can’t get into the brain easily, and that’s one reason brain metastases (cancer spread to the brain) are so hard to treat,” Dr. Carew explained. “But hydroxychloroquine can, which makes it a good candidate.”

Combining Treatments: Hydroxychloroquine and Lapatinib

The team then combined hydroxychloroquine with another FDA-approved drug for breast cancer called lapatinib. In their experiments with mice, this combination reduced both the number and size of breast cancer tumors in the brain.

Hydroxychloroquine has been tested with other cancer drugs before. This, however, is the first time anyone has tried it with lapatinib for breast cancer. The results were impressive.

“Unfortunately, cancer cells are very good at finding ways to survive,” Dr. Carew said. “It’s amazing to see that by changing just one thing, we can have such a big impact.”

A New Path Forward: Clinical Trials and Future Hope

Dr. Steffan Nawrocki, the first author of the study, added, “Our research shows that autophagy helps cancer cells resist many treatments. Since hydroxychloroquine and lapatinib are already approved by the FDA, we can quickly start testing this combination in clinical trials with patients who have breast cancer that has spread to the brain.”

Breast cancer that spreads to the brain is the most common type of tumor in adults’ central nervous systems. About 20% to 30% of these cases start as breast cancer. Especially in patients with certain types like triple-negative and HER2-positive. Only about 20% of these patients survive more than five years.

This study offers new hope and a potential new treatment strategy for these patients. The next step is to test this drug combination in clinical trials to see if it works in humans. The researchers are optimistic that the combination of hydroxychloroquine and lapatinib for breast cancer brain metastases could be a game-changer.

Exciting New Discovery Could Make Chemotherapy Safer for Cancer Patients

New Discovery Could Protect Hearts of Cancer Patients from Chemotherapy Damage, blocking the CDK7 protein can prevent heart damage and enhance cancer treatment effectiveness, Mice being used in a research experiment to study the effects of blocking the CDK7 protein on heart health and cancer treatment

Scientists at Washington State University have made an important discovery that could help make cancer treatments safer for the heart. They found that blocking a protein called CDK7 can protect hearts and boost cancer treatment

Why This Matters

Many cancer patients are treated with a drug called doxorubicin. This drug is very effective at killing cancer cells but can also cause serious damage to the heart. This heart damage might not show up until many years after treatment. It can lead to heart attacks, heart failure, and other heart diseases. This new study could help find ways to reduce these risks and improve the lives of cancer patients.

How They Made the Discovery

The researchers studied mice and found that when they blocked the CDK7 protein, the mice did not suffer from the heart damage usually caused by doxorubicin. They used a special drug called THZ1 to block CDK7. Interestingly, they also found that this drug not only protected the heart. But it also made doxorubicin even better at killing cancer cells.

What’s Next?

The scientists plan to do more research to understand how blocking CDK7 can help both the heart and the cancer treatment. They want to test the effects on younger mice to see if the protection lasts longer. Similar to how heart damage in human cancer survivors can appear many years later. They will also look at other proteins that might be involved in causing heart damage.

Hope for the Future

This discovery is a big step toward making chemotherapy treatments safer by aiming to protect hearts and boost cancer treatment. If future studies confirm these findings, it could lead to new treatments. Thus helping cancer patients live longer and healthier lives.

This important research was published in the journal Cardiovascular Research. As well as supported by the National Heart, Lung, and Blood Institute and the National Cancer Institute.